Tianjin Chase Sun PharmaceuticalLtd Valuation
Is 300026 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 300026 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: 300026 (CN¥3.96) wird über unserer Schätzung des Fair Value (CN¥2.88) gehandelt.
Deutlich unter dem Marktwert: 300026 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 300026?
Other financial metrics that can be useful for relative valuation.
| What is 300026's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CN¥11.87b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2x |
| Enterprise Value/EBITDA | 15x |
| PEG Ratio | 0.9x |
Price to Earnings Ratio vs Peers
How does 300026's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 29.4x | ||
600420 Shanghai Shyndec Pharmaceutical | 17x | 17.9% | CN¥11.8b |
600572 Zhejiang CONBA PharmaceuticalLtd | 16.7x | 15.7% | CN¥12.6b |
002626 Xiamen Kingdomway Group | 60.1x | n/a | CN¥9.1b |
002287 Tibet Cheezheng Tibetan Medicine | 23.6x | n/a | CN¥11.6b |
300026 Tianjin Chase Sun PharmaceuticalLtd | 23.4x | 25.1% | CN¥11.9b |
Price-To-Earnings gegen Gleichaltrige: 300026 ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (22.4x) mit dem Durchschnitt der anderen Unternehmen (23.3x) vergleicht.
Price to Earnings Ratio vs Industry
How does 300026's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: 300026 ist aufgrund seines Price-To-Earnings Verhältnisses (20x) im Vergleich zum CN Pharmaceuticals Branchendurchschnitt (31.3x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 300026's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 23.4x |
| Fair PE Ratio | 26.8x |
PM vs. Fair Ratio: 300026 ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Earnings (17.7x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (22.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.